Systematic review and meta-analysis of the association between Epstein-Barr virus, multiple sclerosis and other risk factors.

Epstein–Barr virus Multiple sclerosis clinically isolated syndrome infectious mononucleosis meta-analysis systematic review

Journal

Multiple sclerosis (Houndmills, Basingstoke, England)
ISSN: 1477-0970
Titre abrégé: Mult Scler
Pays: England
ID NLM: 9509185

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 24 3 2020
medline: 25 9 2021
entrez: 24 3 2020
Statut: ppublish

Résumé

Epstein-Barr virus (EBV) infection is thought to play a central role in the development of multiple sclerosis (MS). If causal, it represents a target for interventions to reduce MS risk. To examine the evidence for interaction between EBV and other risk factors, and explore mechanisms via which EBV infection may influence MS risk. Pubmed was searched using the terms 'multiple sclerosis' AND 'Epstein Barr virus', 'multiple sclerosis' AND EBV, 'clinically isolated syndrome' AND 'Epstein Barr virus' and 'clinically isolated syndrome' AND EBV. All abstracts were reviewed for possible inclusion. A total of 262 full-text papers were reviewed. There was evidence of interaction on the additive scale between anti-EBV antibody titre and HLA genotype (attributable proportion due to interaction (AP) = 0.48, EBV appears to interact with at least some established MS risk factors. The mechanism via which EBV influences MS risk remains unknown.

Sections du résumé

BACKGROUND
Epstein-Barr virus (EBV) infection is thought to play a central role in the development of multiple sclerosis (MS). If causal, it represents a target for interventions to reduce MS risk.
OBJECTIVE
To examine the evidence for interaction between EBV and other risk factors, and explore mechanisms via which EBV infection may influence MS risk.
METHODS
Pubmed was searched using the terms 'multiple sclerosis' AND 'Epstein Barr virus', 'multiple sclerosis' AND EBV, 'clinically isolated syndrome' AND 'Epstein Barr virus' and 'clinically isolated syndrome' AND EBV. All abstracts were reviewed for possible inclusion.
RESULTS
A total of 262 full-text papers were reviewed. There was evidence of interaction on the additive scale between anti-EBV antibody titre and HLA genotype (attributable proportion due to interaction (AP) = 0.48,
CONCLUSION
EBV appears to interact with at least some established MS risk factors. The mechanism via which EBV influences MS risk remains unknown.

Identifiants

pubmed: 32202208
doi: 10.1177/1352458520907901
pmc: PMC7543008
doi:

Types de publication

Journal Article Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1281-1297

Références

Mult Scler. 2008 Sep;14(8):1120-2
pubmed: 18573815
Mult Scler. 2009 Apr;15(4):431-6
pubmed: 19153174
Lancet Neurol. 2015 Mar;14(3):263-73
pubmed: 25662901
Sci Rep. 2015 Dec 11;5:18083
pubmed: 26656273
Arch Neurol. 2007 Jan;64(1):72-5
pubmed: 17210811
Neurology. 2012 Sep 25;79(13):1363-8
pubmed: 22933744
PLoS One. 2013 Apr 09;8(4):e61110
pubmed: 23585874
Mult Scler. 2019 Apr;25(4):515-522
pubmed: 29393768
Mult Scler. 2013 Feb;19(2):162-6
pubmed: 22740437
Nat Rev Neurol. 2017 Jan;13(1):25-36
pubmed: 27934854
JAMA. 2005 May 25;293(20):2496-500
pubmed: 15914750
Mult Scler. 2013 Oct;19(12):1587-91
pubmed: 23549431
Ann Clin Transl Neurol. 2019 Sep;6(9):1905-1922
pubmed: 31392849
JAMA. 2001 Dec 26;286(24):3083-8
pubmed: 11754673
Neurology. 2010 Apr 27;74(17):1365-71
pubmed: 20375311
Epidemiology. 1992 Sep;3(5):452-6
pubmed: 1391139
J Neurol Sci. 2013 Feb 15;325(1-2):86-9
pubmed: 23312038
Ann Neurol. 2010 Feb;67(2):261-5
pubmed: 20225292
Genes Immun. 2012 Jan;13(1):14-20
pubmed: 21776012
Mult Scler. 2016 Apr;22(4):461-9
pubmed: 26199349
Eur J Epidemiol. 2005;20(7):575-9
pubmed: 16119429
J Neurol Neurosurg Psychiatry. 2012 Dec;83(12):1170-3
pubmed: 22888143
PLoS One. 2010 Sep 01;5(9):
pubmed: 20824132
Eur J Neurol. 2015 Mar;22(3):578-e38
pubmed: 25530445
Neurology. 2011 Jul 26;77(4):371-9
pubmed: 21753179
Mult Scler. 2014 May;20(6):747-50
pubmed: 24107308
Neurology. 2008 Mar 25;70(13 Pt 2):1113-8
pubmed: 18272866
Neurol Neuroimmunol Neuroinflamm. 2017 Feb 03;4(2):e318
pubmed: 28203615
J Epidemiol Community Health. 2004 Dec;58(12):1032-5
pubmed: 15547068
Neurology. 2000 Jun 27;54(12):2307-10
pubmed: 10881258
Am J Epidemiol. 1980 Oct;112(4):467-70
pubmed: 7424895
Mult Scler. 2017 Jan 1;24(5):590-603
pubmed: 28671487
Ann Neurol. 2006 Mar;59(3):499-503
pubmed: 16502434
BMJ. 2011 Jul 22;343:d4002
pubmed: 21784880

Auteurs

Benjamin M Jacobs (BM)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Gavin Giovannoni (G)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University, London, UK/Blizard Institute, Queen Mary University of London, London, UK/Royal London Hospital, London, UK.

Jack Cuzick (J)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK.

Ruth Dobson (R)

Preventive Neurology Unit, Wolfson Institute of Preventive Medicine, Queen Mary University of London, London, UK/Royal London Hospital, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH